cardiac surgery – Medxy AI

Postoperative Atrial Fibrillation After Cardiac Surgery: Common, Variably Treated, and Linked to Worse 1-Year Outcomes

By MedXY 06/17/2026

The VISION Cardiac Surgery cohort found POAF in about one-third of patients, with wide variation in discharge treatment. POAF strongly predicted later atrial fibrillation and was associated with higher 1-year mortality.

Cardiology Clinical Updates news

Rethinking Magnesium Prophylaxis for Postoperative Atrial Fibrillation in Cardiac Surgery: A Synthesis of Clinical Evidence

By MedXY 06/02/2026

Recent high-quality randomized clinical trials and meta-analyses suggest that routine magnesium sulfate infusion does not effectively prevent postoperative atrial fibrillation in cardiac surgery, especially when used alongside standard beta-blocker protocols.

Anesthesiology Cardiology news

Perioperative Dexmedetomidine Fails to Reduce Major Complications After Cardiac Surgery: Results from the DOCS Trial

By MedXY 01/07/2026

The DOCS trial, a multi-center randomized controlled study, found that perioperative dexmedetomidine infusion did not significantly reduce in-hospital mortality or major complications in adults undergoing cardiac surgery with cardiopulmonary bypass, challenging the hypothesis of its broad organ-protective benefits.

Cardiology Clinical Updates General Surgery news

Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies

By MedXY 12/13/2025

This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, supported by the recent FARES-II trial and corroborating clinical research.

Clinical Updates General Surgery news

Cryopreserved Versus Liquid-Stored Platelets in Surgical Bleeding: Insights from the CLIP-II Randomized Noninferiority Trial

By MedXY 12/13/2025

The CLIP-II trial evaluated dimethyl sulfoxide-cryopreserved platelets with extended shelf-life against conventional liquid-stored platelets in cardiac surgery bleeding, finding noninferiority was not established and cryopreserved platelets showed reduced hemostatic effectiveness despite similar safety profiles.

Cardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

By MedXY 11/14/2025

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.

Anesthesiology Cardiology General Surgery news

Pathogen-Reduced Red Blood Cells Are Safe in Cardiac Surgery: ReCePI Phase 3 Shows Noninferior AKI Rates

By MedXY 11/05/2025

The ReCePI randomized phase 3 trial found that amustaline/glutathione pathogen-reduced red blood cells produced similar rates of acute kidney injury compared with conventional transfusion after cardiac or thoracic-aorta surgery, with few treatment-emergent antibodies and no clinically significant hemolysis.

Anesthesiology Cardiology news

Acute Normovolemic Hemodilution in Adult Cardiac Surgery: Efficacy, Safety, and Underutilization

By MedXY 10/10/2025

This article reviews a large retrospective study evaluating acute normovolemic hemodilution (ANH) in adult cardiac surgery, demonstrating its association with reduced blood transfusions and cost savings, yet highlighting its underuse in clinical practice.

Cardiology Clinical Updates news Specialties

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY 09/22/2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Cardiology General Surgery news Specialties

Unexpected Risks of Postoperative 20% Albumin Infusion in High-Risk Cardiac Surgery Patients: Insights from the ALBICS AKI Trial

By MedXY 09/13/2025

The ALBICS AKI trial reveals that postoperative infusion of 20% albumin increases acute kidney injury risk in high-risk cardiac surgery patients, challenging prior assumptions about albumin's nephroprotective role in this setting.

AI General Surgery Specialties

Virtual Reality for Reducing Preoperative Anxiety: Insights from Cardiac Surgery Trials and Meta-Analyses of Elective Surgical Procedures

By MedXY 08/21/2025

Virtual reality (VR) interventions show promise in mitigating preoperative anxiety, with clinical trials and meta-analyses indicating moderate but significant anxiolytic effects across surgical populations, especially in cardiac surgery and pediatric patients.

Cardiology General Surgery Nephrology Specialties

Perioperative Nitric Oxide Conditioning in Cardiac Surgery: A Paradigm Shift for Protecting Renal Function in CKD Patients (DEFENDER Trial Review)

By MedXY 08/21/2025

Perioperative nitric oxide administration in CKD patients undergoing cardiac surgery significantly reduces acute kidney injury incidence and preserves renal function, while demonstrating safety and additional benefits against postoperative pneumonia.

Cardiology Clinical Updates news Specialties

Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial

By MedXY 07/31/2025

A large multinational trial found that acute normovolemic hemodilution (ANH) did not significantly reduce allogeneic red-cell transfusion in adult cardiac surgery patients, with similar safety outcomes compared to usual care.